If you are playing golf just for fun or if you want to get into it a little bit more serious, you will probably want to swing the golf club as consistently as possible.
Many people just don’t realize how difficult it is to be consistent with swinging the golf club and you need a lot of practice to master it to a certain degree. This is also one of the traits that makes golf as frustrating as it can be enjoyable. The good thing is you can improve almost infinitely so you have always something to look for.
As with many other sports, making a great swing consists out of many details, how you stand on the ground, how you hold your golf club, how bent are your knees and many other things that come into play.
Most important tips for a consistent swing
Mastering the stance
Everything starts with how you stand. You have to be comfortable and you have to be stable.
Align your body
Your body needs to be perfectly aligned if you want to master your swing. Your upper body should be pointed slightly to the ball you are trying to hit.
Bend your knees
You have to bend your knees, this will make you more stable and it will also make your stance more dynamic and ready for that swing.
Perfect your grip
How you hold your grip determines how you swing your club. You want to be relaxed yet have a firm grip so you can control the club correctly.
How to swing the club
Now this is the most important part and also the most complex one.
Steps of the swing:
- Start with upswing
- Follow through with your downswing
- Make sure to have the shaft leaning forward toward the target at the moment of impact
- Follow through with the swing
- Don’t force the swing, let it come naturally
The approval of the drug will bring a new window of opportunity for the companies, both geographically and therapeutically
Biogen Inc (NASDAQ:BIIB) and Ionis have been filling their mutual investigational molecule nusinersen for the New Drug Application (NDA) to the Food and Drug Administration (FDA). The molecule is indicated for the management and treatment of type-1 spinal muscular atrophy (SMA).
In August 2016, both the drugmakers have published their ENDEAR clinical study results in relation to the SMA type 1 disease with achievement of the primary endpoints. With reference to the results, the companies have shifted patients in an Open Label Extension Study from clinical trial. The investigational molecule has shown drastic improvement in the motor symptoms of patients receiving the drug.
Biogen has worldwide rights of the drug, for which it has paid $75 million to Ionis. The company has to pay other royalties for the clinical trials, regulatory approvals and marketing of the drug. In addition, Ionis is eligible to get $150 million in downstream payments in relation to the regulatory milestones.
MDA has provided $750,000 to Adrian Krainer at Cold Spring Harbor Laboratory in New York for the clinical research on the early stage patients of SMS to vitalize the role of nusinersen. Otherwise, MDA has invested approximately $45 million to ascertain and develop the role of nusinersen to look for other pathological aliments.
Moreover, the companies are planning for the submission of the drug to European Medicines Agency (EMA) in October 2016 and other geographical areas by the end of 2016. The EMA committee for Medicinal Products for Human Use (CHMP) has given approval for Accelerated Assessment reducing the standard protocol time.
Spinal muscular atrophy (SMA) is a debilitating disease affecting the patients via muscle wasting due to nerve cell degeneration. Approximately one in 10,000 live births are affected by this disease. According to Biogen’s statistics, there are 35,000 infant patients suffering from the debilitating disease across US, Europe, and Japan.
There is no treatment available till date for the disease and if approved, the drug can generate $1 billion on yearly basis. The molecule has already gained secured status due to its vitality in the US and Europe and is expected to gain approval from the regulatory agencies keeping in view of the important role it has to play.
Mozilla’s co-founder Brendan Eich’s Brave Browser will now pay users in bitcoins to view ads that they want, in the browser’s ad replacement mode
Brave is available on a wide range of desktop and mobile operating systems like Windows, Mac, Linux, iOS and Android. The idea behind the plan to pay users for viewing ads is that ads with malicious intent with tendency to invade the privacy will be blocked. In their stead, ads from trusted networks will be shown, and not just for nothing. The users will then be compensated in bitcoins for the trouble of viewing the ads approved by the browser in the first place. The only tracking Brave promises to do is the sort which would allow the browser to analyze a particular user’s browsing habits, in order to display more relevant ads.
The ads approved for viewing will not contain any sensitive content, without putting the identity of any viewer at any sort of risk. The compensation for viewing ads was previously hinted at by Brendan Eich, who said that the revenue would be shared with both publishers and users. Once the advertisers pay up for a certain number of viewings or impressions, the amount would then be accumulated into an aggregate pool. The approved payment plan from ad-networks for all parties was would then be as following: –
- 55% for Publishers
- 15% for Brave
- 15% for Ad-Matching Partner
- 1%% for Users
Payments would be credited to a Bitcoin Wallet verified user-to-user by phone numbers and email addresses. A micropayment system, called “Brave Ledger”, would also be available for users choosing to donate to publishers.
On the other hand, users will have the option to pay and block all sorts of ads, pay certain publishers to block their ads, or even go full ad-block mode without making any payment at all. All these avenues would be at hand for the user to explore, with secure micropayments at the helm of the whole business model.
Brave 1.0 Development release should be ready for release sometime next month, by which time this proposed payment plan would be approved from feedback. Users can, however, seek the risk-free – and return free – option of not paying and not being paid for any ads. But the innovative idea and fairly proper implementation and division of the accumulated pool does seem like a proposition that should be discussed.